119 results on '"Létourneau, Myriam"'
Search Results
2. Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands
3. Protein context shapes the specificity of SH3 domain-mediated interactions in vivo
4. Al[18F]F-complexation of DFH17, a NOTA-conjugated adrenomedullin analog, for PET imaging of pulmonary circulation
5. Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin
6. Optimization of on-resin palladium-catalyzed Sonogashira cross-coupling reaction for peptides and its use in a structure–activity relationship study of a class B GPCR ligand
7. Insight into the role of urotensin II-related peptide tyrosine residue in UT activation
8. A conserved SH3-like fold in diverse putative proteins tetramerizes into an oxidoreductase providing an antimicrobial resistance phenotype.
9. Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide
10. Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinsonʼs disease model
11. Tunable Surface Charge Enables the Electrostatic Adsorption-Controlled Release of Neuroprotective Peptides from a Hydrogel–Nanoparticle Drug Delivery System.
12. Photoreleasable ligands to study intracrine angiotensin II signalling
13. Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging
14. Urocontrin, a novel UT receptor ligand with a unique pharmacological profile
15. Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects
16. Perturbing dimer interactions and allosteric communication modulates the immunosuppressive activity of human galectin-7.
17. Development and pharmacological characterization of “caged” urotensin II analogs
18. PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors
19. Binding of a Soluble meso-Tetraarylporphyrin to Human Galectin‑7 Induces Oligomerization and Modulates Its Pro-Apoptotic Activity.
20. Genome sequencing and functional characterization of a Dictyopanus pusillus fungal enzymatic extract offers a promising alternative for lignocellulose pretreatment of oil palm residues.
21. Semi‐rational evolution of the 3‐(3‐hydroxyalkanoyloxy)alkanoate (HAA) synthase RhlA to improve rhamnolipid production in Pseudomonas aeruginosa and Burkholderia glumae.
22. Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide.
23. New insights about the peculiar role of the 28–38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection.
24. How to improve PACAP efficiency for neuroprotection and neurorepair?
25. Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity.
26. Development of agonists of endothelin-1 exhibiting selectivity towards ETA receptors
27. MOLECULAR IMAGING OF THE HUMAN PULMONARY VASCULAR ENDOTHELIUM IN PULMONARY HYPERTENSION: THE PULMOBIND SAFETY AND PROOF OF PRINCIPLE TRIAL
28. Molecular Imaging of the Human Pulmonary Vascular Endothelium Using an Adrenomedullin Receptor Ligand.
29. Design of a Truncated Cardiotoxin-IAnaloguewith Potent Insulinotropic Activity.
30. Development and PharmacologicalCharacterization ofConformationally Constrained Urotensin II-Related Peptide Agonists.
31. PulmoBind, an Adrenomedullin-Based Molecular Lung Imaging Tool.
32. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.
33. Cardiotoxin-I: An Unexpectedly Potent Insulinotropic Agent.
34. Presence of urotensin-II receptors at the cell nucleus: Specific tissue distribution and hypoxia-induced modulation
35. Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine
36. Identification of ETA and ETB binding domains using ET-derived photoprobes
37. Study of solid-phase synthesis and purification strategies for the preparation of polyglutamine peptides.
38. PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors
39. Development of agonists of endothelin-1 exhibiting selectivity towards ET[subΑ]receptors.
40. Ancestral sequence reconstruction dissects structural and functional differences among eosinophil ribonucleases.
41. Dealing with the Aggregation Problem of Polyglutamine Peptides: Synthesis Strategies.
42. New Short Peptide Substrates of Endothelin-Converting Enzyme and Characterization of the Enzyme.
43. Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease.
44. Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide
45. Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor.
46. Conformational exchange divergence along the evolutionary pathway of eosinophil-associated ribonucleases.
47. Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands
48. Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP
49. Perturbing dimer interactions and allosteric communication modulates the immunosuppressive activity of human galectin-7.
50. Insights into Structural and Dynamical Changes Experienced by Human RNase 6 upon Ligand Binding.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.